FDA Wants More Info On New Schizophrenia Drug Trials
The U.S. Food and Drug Administration has asked for more information on clinical trials related to Intra-Cellular Therapies Inc.'s new schizophrenia medication lumateperone, but the company on Monday said it still...To view the full article, register now.
Already a subscriber? Click here to view full article